Patents-Review.com
ClassID:

110626 ⎘

C12N2760/10034 - CPC Classification

Classification description:

ssRNA viruses negative-sense; Details; Arenaviridae Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Recent Application in this class:
#1
20260144820
2026-05-28

ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY

 #2
20260109736
2026-04-23

TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS

 #3
20260053910
2026-02-26

HBV VACCINES AND METHODS TREATING HBV

 #4
20260041757
2026-02-12

THERMOSTABLE MUCOSAL VACCINE COMPOSITIONS AND METHODS

 #5
20250369015
2025-12-04

REPLICATION-DEFECTIVE ARENAVIRUS VECTORS

 #6
20250250304
2025-08-07

RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING LASSA VIRUS GP OR NP, AND USES THEREOF

 #7
20250213672
2025-07-03

LIVE ATTENUATED JUNIN VIRUS AND RELATED COMPOSITIONS AND METHODS

 #8
20250213670
2025-07-03

MULTIVALENT MOPEVAC-BASED IMMUNOGENIC COMPOSITION FOR VACCINATION AGAINST NEW WORLD ARENAVIRUSES AND THERAPEUTIC USE(S) THEREOF

 #9
20250134976
2025-05-01

COMPOSITIONS FOR INDUCING INTRATUMORAL IMMUNE TRIADS AND USES THEREOF

 #10
20250108101
2025-04-03

Non-Oncolytic Virus Infected Dead Cancer Cell Vaccine

 #11
20250073324
2025-03-06

MODIFIED ARENAVIRUS PARTICLES EXPRESSING MUTANT KRAS, MUTATED CANCER DRIVER GENE, OR TUMOR-ASSOCIATED ANTIGEN AS CANCER IMMUNOTHERAPIES

 #12
20250057931
2025-02-20

COMBINATION THERAPY WITH ARENAVIRUS PARTICLES AND IMMUNE CHECKPOINT MODULATORS OR CYTOKINES

 #13
20250034213
2025-01-30

ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS, METHODS AND USE THEREOF

 #14
20240228549
2024-07-11

PREFUSION-STABILIZED LASSA VIRUS GLYCOPROTEIN COMPLEX AND ITS USE

 #15
20240174724
2024-05-30

ARENAVIRUSES USED IN TREATMENTS OF PROSTATE CANCER

 #16
20240156940
2024-05-16

REPLICATION-DEFICIENT MODIFIED VACCINIA ANKARA (MVA) EXPRESSING MARBURG VIRUS GLYCOPROTEIN (GP) AND MATRIX PROTEIN (VP40)

 #17
20240082376
2024-03-14

TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS

 #18
20240066117
2024-02-29

HBV VACCINES AND METHODS TREATING HBV

 #19
20240041996
2024-02-08

ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPY

 #20
20230310568
2023-10-05

ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF

 #21
20230181713
2023-06-15

Lassa virus vaccine

 #22
20230114007
2023-04-13

HBV vaccines and methods treating HBV

 #23
20220380805
2022-12-01

ARENAVIRUSES AS VECTORS

 #24
20220315951
2022-10-06

Replication-defective arenavirus vectors

 #25
20220289797
2022-09-15

TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS

 #26
20220152190
2022-05-19

Replication-deficient modified vaccinia Ankara (MVA) expressing glycoprotein (GP) and matrix protein (VP40)

 #27
20220127309
2022-04-28

Chimeric molecules and uses thereof

 #28
20220040284
2022-02-10

VACCINES AND METHODS

 #29
20210260178
2021-08-26

NOVEL LASSA VIRUS RNA MOLECULES AND COMPOSITIONS FOR VACCINATION

 #30
20210230633
2021-07-29

NUCLEOTIDE VACCINE

 #31
20210205436
2021-07-08

Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity

 #32
20210145950
2021-05-20

TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS

 #33
20210093712
2021-04-01

HBV vaccines and methods treating HBV

 #34
20210071198
2021-03-11

Replication-defective arenavirus vectors

 #35
20210000935
2021-01-07

Activation of resident memory T cells for cancer immunotherapy

 #36
20200308555
2020-10-01

Lassa vaccine

 #37
20200223926
2020-07-16

COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS

 #38
20200113995
2020-04-16

ARENAVIRUS PARTICLES TO TREAT SOLID TUMORS

 #39
20200040042
2020-02-06

Chimeric molecules and uses thereof

 #40
20190351044
2019-11-21

Lassa virus vaccine

 #41
20190192654
2019-06-27

Microparticulated Vaccines for the Oral or Nasal Vaccination and Boostering of Animals Including Fish

 #42
20190135875
2019-05-09

TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS

 #43
20190117758
2019-04-25

Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)

 #44
20190062784
2019-02-28

Replication-defective arenavirus vectors

 #45
20190031758
2019-01-31

COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS

 #46
20180360958
2018-12-20

Vaccines with interleukin-33 as an adjuvant

 #47
20180325952
2018-11-15

Activation of resident memory T cells for cancer immunotherapy

 #48
20180319845
2018-11-08

Vaccines against hepatitis B virus

 #49
20180303927
2018-10-25

Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity

 #50
20180155430
2018-06-07

COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS

 #51
20180015160
2018-01-18

In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus-Like Particles

 #52
20170319673
2017-11-09

Tri-segmented arenaviruses as vaccine vectors

 #53
20170196964
2017-07-13

Arenavirus vaccine

 #54
20170146520
2017-05-25

METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS

 #55
20160235838
2016-08-18

Vaccines with interleukin-33 as an adjuvant

 #56
20160206724
2016-07-21

Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)

 #57
20160194663
2016-07-07

Replication-defective arenavirus vectors

 #58
20150320855
2015-11-12

IN VIVO ACTIVATION OF ANTIGEN PRESENTING CELLS FOR ENHANCEMENT OF IMMUNE RESPONSES INDUCED BY VIRUS-LIKE PARTICLES

 #59
20150140028
2015-05-21

Recombinant bacterium and uses thereof

 #60
20140255445
2014-09-11

Synthetic viruses and uses thereof

 #61
20140249467
2014-09-04

Cross-protective arenavirus vaccines and their method of use

 #62
20120263754
2012-10-18

Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines

 #63
20120251537
2012-10-04

COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS

 #64
20120231030
2012-09-13

Multi-epitopic vaccine

 #65
20120219576
2012-08-30

LASSA VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF

 #66
20120046638
2012-02-23

Method of inducing a CTL response

 #67
20120040010
2012-02-16

Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish

 #68
20110293649
2011-12-01

In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus Like Particles

 #69
20110129496
2011-06-02

Use of mTOR inhibitors to enhance T cell immune responses

 #70
20110014227
2011-01-20

Pre-or post-exposure treatment for filovirus or arenavirus infection

 #71
20100297172
2010-11-25

Replication-defective arenavirus vectors

 #72
20100278904
2010-11-04

NUCLEOTIDE VACCINE

 #73
20100151492
2010-06-17

Methods for the treatment of infections and tumors

 #74
20100098722
2010-04-22

Packaging of Immunostimulatory Substances Into Virus-Like Particles: Method of Preparation and Use

 #75
20100040614
2010-02-18

COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS

 #76
20090035252
2009-02-05

Method of inducing a CTL response

 #77
20080206282
2008-08-28

Chimeric lyssavirus nucleic acids and polypeptides

 #78
20060251677
2006-11-09

Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use

 #79
20060251623
2006-11-09

Packaged virus-like particles

 #80
20060193872
2006-08-31

Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers

 #81
20060153858
2006-07-13

Method of inducing a CTL response

 #82
20050064389
2005-03-24

Chimeric lyssavirus nucleic acids and polypeptides